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Abstract
Background: Visceral leishmaniasis (VL) can be fatal without timely diagnosis and treatment. Treatment efficacies
vary due to drug resistance, drug toxicity and co-morbidities. It is important to monitor treatment responsiveness to
confirm cure and curtail relapse. Currently, microscopy of spleen, bone marrow or lymph node biopsies is the only
definitive method to evaluate cure. A less invasive test for treatment success is a high priority for VL management.
Methods: In this study, we describe the development of a capture ELISA based on detecting Leishmania donovani
antigens in urine samples and comparison with the Leishmania Antigen ELISA, also developed for the same purpose.
Both were developed as prototype kits and tested on patient urine samples from Sudan, Ethiopia, Bangladesh and
Brazil, along with appropriate control samples from endemic and non-endemic regions. Sensitivity and specificity were
assessed based on accurate detection of patients compared to control samples. One- Way ANOVA was used to assess
the discrimination capacity of the tests and Cohen’s kappa was used to assess their correlation.
Results: The Leishmania Antigen Detect™ ELISA demonstrated >90 % sensitivity on VL patient samples from Sudan,
Bangladesh and Ethiopia and 88 % on samples from Brazil. The Leishmania Antigen ELISA was comparable in
performance except for lower sensitivity on Sudanese samples. Both were highly specific. To confirm utility in
monitoring treatment, urine samples were collected from VL patients at days 0, 30 and 180 post- treatment. For
the Leishmania Antigen Detect™ ELISA, positivity was high at day 0 at 95 %, falling to 21 % at day 30. At day 180, all
samples were negative, corresponding well with clinical cure. A similar trend was also seen for the Leishmania Antigen
ELISA albeit; with lower positivity of 91 % at Day 0 and more patients, remaining positive at Days 30 and 180.
Discussion: The Leishmania Antigen Detect™ and the Leishmania Antigen ELISAs are standardized, user- friendly,
quantitative and direct tests to detect Leishmania during acute VL as well as to monitor parasite clearance during
treatment. They are a clear improvement over existing options.
Conclusion: The ELISAs provide a non-invasive method to detect parasite antigens during acute infection and monitor
its clearance upon cure, filling an unmet need in VL management. Further refinement of the tests with more samples
from endemic regions will define their utility in monitoring treatment.
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Background
Visceral Leishmaniasis (VL) is a sand fly-borne disease
caused by infection with protozoan parasites of the
Leishmania donovani complex. The vast majority of the
300,000 estimated annual cases are reported from focal re-
gions in Ethiopia, Sudan, South Sudan, India, Bangladesh
and Brazil, though the disease is also endemic in the
Mediterranean basin [1]. VL incidence is highest in the In-
dian sub- continent, followed by East Africa, where the
causative organism is L. donovani and transmission is
anthroponotic. In Brazil and the Mediterranean basin, the
disease is caused by L. infantum, while transmission is
zoonotic, with dogs serving as an intermediary host [1].
VL incidence has also been reported in previously non-
endemic regions owing to travel to and migration from
endemic regions and environmental conditions that have
expanded the habitat of the sand fly [2–4]. Current diag-
nosis of VL is based on presentation of clinical symptoms
such as fever, splenomegaly and weight loss, then con-
firmed by parasite detection in bone marrow/splenic bi-
opsy in Africa and South America; or detection of
antibodies against the rK39 antigen in the Indian subcon-
tinent [5].
Multiple drug regimens are available to treat VL. Anti-
moniates including sodium stibogluconate (SSG) and
meglumine antimoniate (MEG) are the first line drugs in
Brazil and Africa, while resistance to antimoniates have
phased them out in the Indian sub- continent, where
amphotericin B, paromomycin and miltefosine are the
drugs of choice [6, 7]. Liposomal amphotericin B (AmBi-
some™) is now preferred in Europe and the Indian sub-
continent [8].
Timely diagnosis and treatment are imperative as, with-
out treatment, VL can be fatal [1, 6]. Drug regimens are
expensive and can cause severe side effects [5, 6, 9]. These
factors have contributed to low compliance in many VL
endemic regions, leading to unresponsiveness and the
emergence of drug- resistant parasite strains [7, 9]. It is im-
portant to monitor treatment and detect unresponsiveness
as early as possible. Treatment failure ranges from 3–10 %
in immune competent individuals and 50–60 % in immune
compromised individuals [4, 10]. Though simple tests are
available to accurately confirm VL disease, none of the
current diagnostic tests is suitable to monitor treatment or
cure [11]. Commonly used diagnostic tests such as DAT
and the rK39 rapid detection test (RDT) cannot differenti-
ate between past and current infections because the anti-
bodies detected persist after clinical cure is achieved [12].
Microscopy of splenic or bone marrow biopsies, though
confirmatory for parasite clearance is not a practical tool
to monitor treatment due to the painful and invasive
nature of sampling.
A non-invasive, standardized test for monitoring treat-
ment success in a clinical setting would complement
tools to confirm VL, and aid in effectively managing VL.
Such a test should ideally detect parasite or parasite
products as a measure of infection since presence of
parasite products should theoretically correlate with
parasite burden. Hence, a drop in antigen levels as mea-
sured by the test would reflect a decrease in parasite
burden due to anti-Leishmania treatment and eventual
clearance of parasites. It must also be sensitive, specific,
easy to use, quantitative and preferably non- invasive for
repeated sample collection.
At present, KAtex is the only commercially available
Leishmania antigen detection test [13]. Although highly
specific, KAtex’s sensitivity has been variable, limiting its
widespread use for the assessment of treatment [14–17].
Knowing that Leishmania antigens are excreted in the
urine of VL patients, we developed a sensitive urine-
based test to detect antigens with which to evaluate
treatment [18, 19]. We compared its performance to a
similar product developed by Kalon Biological Ltd., UK.
We discuss the validation of the antigen detection tests




Urine samples of VL patients were collected as part of
routine diagnosis and treatment. Except the post- treat-
ment samples, all VL patient samples were collected at
diagnosis prior to treatment start. Samples were col-
lected at Gedaref Hospital, Sudan the Rajshahi Medical
College Hospital, Bangladesh and at the clinic in Sergipe,
Aracaju, Brazil. Urine samples from Ethiopia were col-
lected in Southern Ethiopia during ongoing field studies.
Each of the Ethics Committees of Khartoum University,
Rajshahi Medical College, University of Sergipe and Addis
Ababa University approved study protocols, respectively.
Written or verbal informed consent was obtained from
patients at the time of collection. Inclusion criteria for VL
patients in Ethiopia, Sudan and Brazil were presentation of
clinical symptoms and demonstration of parasites in
spleen, bone marrow, or lymph node smear or positive
rK39 for Bangladesh. Urine samples from patients with
other diseases (OD) were kindly provided by FIND, Geneva
and consisted of 10 each from patients with human African
trypanosomiasis (HAT) and P. falciparum malaria from
Uganda, and 10 from TB patients in Thailand. For all sam-
ples provided by FIND, written, informed consent was
obtained at the time of collection. Non-endemic control
(NEC) samples (n = 49) were collected from local volun-
teers in Seattle, USA or purchased from Equitech-Bio, Inc.
(Kerrville, TX). Urine samples from 10 healthy endemic
controls (EC) were also obtained from Bangladesh as
evidenced by lack of symptoms and a negative rK39-RDT.
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All urine samples were stored frozen and transported on
dry- ice to minimize any adverse effects of freeze- thawing.
Generation of anti-Leishmania antibodies
L. donovani (MHOM/SD/00/1S-2D) promastigotes were
seeded in culture flasks and cultured at 25 °C in M199
medium (Sigma, St. Louis, MO) supplemented with 10 %
FCS (Hyclone), 1XM199 Hanks salt, 1XMEM amino acids
Solution (Invitrogen), 10 mM MEM non-essential amino
acids (Sigma), 40 mM HEPES pH 7.4, 0.1 mM adenine,
5 μg/mL hemin, 1.5 uM biotin, 100 U/mL penicillin,
100 μg/mL streptomycin, 2 mM L-glutamine, 0.35 mg/mL
sodium biocarbonate at final pH 7.2 for 10 days. Station-
ary phase promastigotes at a density of 2-4×107 parasites/
mL were harvested and washed three times with cold PBS
and frozen at −80 °C. To prepare lysates, the pelleted par-
asites were and resuspended in 10 mM Tris–HCl, 1 mM
EDTA (pH 8.0) containing 1X Halt protease inhibitor
(ThermoScientific) at 1×109 parasites/mL. Whole cell lys-
ate (WCL) was prepared by freeze thawing the pellet in
liquid nitrogen (6X) followed by three rounds of sonication
for 30 s at 10 Hz. Soluble lysate antigen (SLA) was
obtained by further centrifuging at 15,000 rpm for 45 min
and discarding the insoluble pellet.
To generate antibodies, New Zealand white rabbits
(NZW) with low residual reactivity to WCL were selected
and immunized with 0.5 mg WCL added complete
Freund’s adjuvant (Sigma) followed by 3 booster immu-
nizations with 0.25 mg WCL with incomplete Freund’s
adjuvant (Sigma) at 3 week intervals. Blood was col-
lected 2 weeks after the final boost (R & R Research,
LLC., Stanwood, WA).
Affinity purification and labeling
Total IgG was purified from the anti-sera of three rabbits
with high IgG titers using Protein G Sepharose. Total IgG
was further affinity purified against SLA coupled with
Cyanogen bromide (CNBr)-activated-Sepharose™ 4B (GE
Healthcare). Affinity purified antibodies were conjugated
with horseradish peroxidase (HRP labeling kit, Thermo-
fisher) at a 6:1 molar ratio using sodium periodate
(NaIO4) and sodium cyanoborohydride (NaBH4CN) for
oxidation and reduction, respectively. Protein concentra-
tion was determined using Bradford’s method and 0.77
volume of glycerol was added to the conjugated antibodies
before storage at −20 °C.
Capture ELISA optimization
ELISA conditions were optimized in the context of
ELISA plate selection, capture and detection antibody
concentrations, urine sample dilution as well as sample
incubation duration. In brief, Immulon™ 2HB plates were
coated with 1 μg/mL affinity purified antibodies in
0.1 M sodium bicarbonate- carbonate buffer (pH9.6) at
4 °C overnight. After blocking with 1 % BSA-PBS/PBS-T,
50 uL of 1:1 diluted urine samples were added and
allowed to incubate at room temperature for 1 h on a
shaker. After 5 washes with 1X PBS/PBS-T, 100 μL of
HRP-labeled anti-SLA IgG was added to each well at
1:1000 dilution and the plate was incubated at room
temperature for 1 h. After five washes, 100 μL of Sure-
Blue™TMB peroxidase substrate (KPL, Inc.) was added
and incubated for 5 min before the reaction was stopped
with 50 μL of 1 N H2SO4. Optical density was read at
450 nm (VersaMax microplate reader, Molecular devices)
immediately. Affinity purified and labeled antibodies were
then transferred to InBios International Inc., Seattle for
developing the Leish Antigen Detect™ ELISA.
Leishmania Antigen Detect™ ELISA
ELISA was performed according to the manufacturer’s
instructions (InBios International Inc. Seattle, WA). In
brief, plate controls (positive and negative) and test sam-
ples were diluted with ELISA dilution buffer at 1:1 ratio
and 50 μl added to duplicate wells for incubation at 37 °C
for 30 min. After 6 washes, 50 μl of HRP-Leishmania
ELISA conjugate was added to each well and allowed to
incubate at 37 °C for 30 min. After washing, 75 μl of TMB
solution was added to each well for 10 min. Reactions
were terminated by adding 50 μl of stopping solution, and
plates were read immediately at 450 nm. Each plate was
assessed passed based on the discrimination between
the signals observed for the in-built positive and nega-
tive controls, with criterion being a Positive control/
negative control >5. For determining the specificity of
the ELISA, ROC curves were generated as described
below. For determining positivity of samples, cut- offs
were generated based on a panel of NEC samples run
in each plate. Samples with signals over the cut- off
were deemed positive.
KAtex
KAtex agglutination tests were conducted following man-
ufacturer’s instructions (Kalon Biological Ltd., Guildford,
UK), with minor modifications. In brief, 200 μl of freshly
thawed urine was transferred into a collection tube, sub-
merged in boiling water for five minutes and then cooled
to room temperature. 50 μl of the boiled urine was added
to the reaction zone on the glass slide and mixed with one
drop of well-mixed latex. The liquids were mixed with a
toothpick and spread to cover the entire surface of the
reaction zone. The glass slide was tilted with a rotating
action, and the degree of agglutination interpreted as
instructed.
Leishmania Antigen ELISA
Leishmania antigen ELISA produced by Kalon Biologicals
Ltd., UK was provided by FIND, Geneva, Switzerland.
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Polyclonal antibodies were prepared from antiserum of
sheep immunized with 4×109 cultured promastigotes from
Leishmania donovani strains from Sudan (LV9), Nepal
(BPK282). Antisera were purified using an antigen affinity
column prepared using concentrated BPK 282 spent cell
culture. Kits were used according to the manufacturer’s
instructions. Briefly, samples were diluted 1:20 in assay di-
luent, after which 100 ul/well of these and antigen calibra-
tors were added to 96-well plates in triplicate or duplicate,
respectively. Plates was incubated for 30 min at 37 °C,
then washed 5 times before the addition of 100 uL of 1X
Tracer. After 30 min of incubation at 37 °C plates were
washed and 100 ul/well TMB Substrate solution was
added for 30 min. Reactions were terminated by adding
100 ul/well of Stop solution. Plates were then read imme-
diately at 450 and 620 nm (VersaMax microplate reader,
Molecular Devices). Resulting OD was obtained by sub-
traction of OD at 620 nm from OD at 450 nm. Urinary
antigen unit (UAU)/mL of samples were extrapolated
from a four parameter logistic standard curve con-
structed in Excel using the mean values obtained for
the calibrators. Samples with UAU less than the lowest
calibrator (2 UAU/mL) were considered negative.
Calculations and statistical analysis
GraphPad Prism six software was used for generating
Receiver-operating characteristic (ROC) curves and stat-
istical analysis. ROC curves were generated with non-VL
(NEC, OD) and VL samples to determine thresholds that
afforded the best specificity. Sensitivity was calculated as
the percentage of VL samples correctly assayed as positive
while specificity was calculated as the percentage of non-
VL samples (NEC, OD) correctly assayed as negative. Area
under the curve (AUC) used to assess the accuracy of each
test. One-way ANOVA (Dunnett’s multiple comparison)
was performed between VL and non- VL samples
with p values ≤0.05 were considered statistically
significant. Cohen’s kappa values were used to deter-
mine the correlation between the ELISAs.
Results
Capture ELISA validation
To establish the performance of the affinity purified anti-
body pair for incorporation into a capture ELISA test,
initial assays using urine samples either spiked with WCL
or from confirmed VL patients were used. A serial dilu-
tion of WCL added to pooled urine samples from healthy
non- endemic controls (NEC) ranging from 4–32 ng/mL
was used to estimate the detection limits (Fig. 1a). Robust
signals were observed across the concentration range with
the lower limit of detection being 4 ng/mL. Hence a broad
range of detection was obtained with the antibody pair.
We then tested whether Leishmania antigens could be
detected in the urine of VL patients. Compared to urine
from healthy NEC, samples from 29 confirmed VL
patients (12 from Sudan, six from Bangladesh and 11
from Brazil) had significantly higher signals, with 22/29
(76 %) testing positive (Fig. 1b). Detection of VL patients
was also highly specific, with signals being significantly
higher than those of patients with other diseases (OD).
Taken together, these data indicated that, the antibody
pair could specifically detect Leishmania antigens in
urine in a laboratory-based capture ELISA.
Performance of Leishmania Antigen Detect™ ELISA
The antibody pair characterized in a laboratory-based
capture ELISA was then incorporated into ready-to-use,
standardized Leishmania Antigen Detect™ ELISA kits
with in- built positive and negative controls, optimized
reagents and assay steps. We assessed the performance
of the Leishmania Antigen Detect™ ELISA on an ex-
panded panel of urine samples from VL patients in 4
major endemic regions although only 13 urine samples
were available from the Indian subcontinent compared
Fig. 1 Optimization of antigen capture ELISA using affinity purified and labeled antibody pair. a. Standard curve was generated using pooled urine from
NEC spiked with 0, 4, 8, 16 and 32 ng/mL of Ld WCL for determining limits of detection of the antibody pair. b. Performance of capture ELISA on urine
samples from VL patients (n= 29), OD (n= 7) and NEC (n= 8). * and ** represent significant p-values < 0.05, as calculated by One-way ANOVA
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to 46, 64 and 43 from Ethiopia, Sudan and Brazil,
respectively. Leishmania antigens were readily detected
in the majority of urine samples from VL patients from
Ethiopia, Sudan and Bangladesh where L. donovani is
the causative agent, with significantly higher signals than
NEC and OD (Fig. 2). Responses were also significantly
higher than the 48 NEC, 10 EC and 30 OD samples
(Fig. 2). Based on the cut- off for positivity generated
against the non- VL samples, high sensitivities of 100 %
for Bangladesh (95 % CI of 75.3-100), 96.9 % for Sudan
(95 % CI of 89.2-99.6), 93.5 % for Ethiopia (95 % CI of
82.1-98.6) and 88.4 % for Brazil (95 % CI of 77.8-96)
were calculated for the Leishmania Antigen Detect™
ELISA (Table 1). Considering the control samples evalu-
ated, the specificity of the assay was 100 % (95 % CI of
90.3-100 for NEC and 69.2-100 for OD) (Table 2).
We observed that the sensitivity of the test was
enhanced when transferred form a laboratory-based cap-
ture ELISA assay (76 %) to the standardized Leishmania
Antigen Detect™ ELISA (>90 %) which was largely due
to the increased discrimination between controls and VL
patients (Fig. 1b and Table 1). This is borne out by the
lower background reactivities to the NEC and OD sam-
ples and the two-fold lower cut- off value for positivity,
observed with the standardized Leishmania Antigen De-
tect™ ELISA (0.12) compared to the laboratory developed
capture ELISA (0.25) (Figs. 1b and 2a). The enhanced
performance further attests to the value of standardized
kits in diagnostics over laboratory- based assays (Fig. 2b).
Altogether, this data demonstrate that the Leishmania
Antigen Detect™ ELISA can detect VL specific antigens
in urine samples from the major endemic regions.
Comparable performance of the Leishmania Antigen ELISA
To provide a sensitive and quantitative assay, Kalon Bio-
logical, Ltd., UK generated a prototype antigen-detection
capture ELISA using sheep anti-Leishmania antibodies. In
the Leishmania Antigen ELISA, antigen concentrations
are calibrated from a standard curve with known concen-
tration of antigens and expressed as Urine Antigen Units
(UAU)/mL (Fig. 3a). Measured UAU/mL in urine samples
from VL patients were significantly higher in Ethiopia,
Sudan and Brazil compared to NEC, EC and OD (Fig. 3b).
Sensitivities of 77 % for Bangladesh (95 % CI of 46.2-95.0),
Fig. 2 Performance of Leishmania Antigen Detect™ ELISA. a. Performance of Leishmania Antigen Detect™ ELISA on urine samples from VL patients in
Ethiopia (n= 46), Sudan (n= 64), Bangladesh (n= 13) and Brazil (n= 43) compared to NEC (n= 49), EC from Bangladesh (n= 10) and OD (n= 30). OD
consists of samples from patients with HAT (n= 10), P. falciparum malaria (n= 10) and tuberculosis (n= 10). Lines represent median. Dotted line indicates
cut-off value for positivity as calculated from the mean of NEC added three standard deviations. **** represents significant p-values < 0.01, as calculated
by One-way ANOVA. b. The standardized Leishmania Antigen Detect™ ELISA offers higher sensitivity for VL patient samples and lower background
reactivity when compared to the same reagents used in a laboratory- based assay
Table 1 Sensitivity of the Leishmania Antigen Detect™ ELISA and the Leishmania Antigen ELISA on VL patient urine compared
to KAtex
Leishmania Antigen™ Detect ELISA Sensitivity % (95% CI) Leishmania Antigen ELISA Sensitivity % (95% CI) KAtex %
Ethiopia (n=46) 93.5 (82.1-98.6) 87.0 (73.7-95.1) 61 (45.4-74.9)
Sudan (n=64) 96.9 (89.2-99.6) 78.1 (66.0-87.5) 63 (49.5-74.3)
Bangladesh (n=13) 100 (75.3-100) 76.9 (46.2-95.0) 69 (38.6-90.7)
Brazil (n=43) 88.4 (77.8-96) 81.4 (66.6-91.6) 56 (39.9-70.9)
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78.1 % for Sudan (95 % CI of 66.0-87.5), 87 % for Ethiopia
(95 % CI of 73.7-95.1) and 81 % for Brazil (95 % CI of
66.6-91.6) were calculated for the Leishmania Antigen
ELISA (Table 1). However, two urine samples from
patients with OD, notably TB and malaria were positive
by the Leishmania Antigen ELISA, displaying antigens
well above the lower threshold of detection defined by the
standard curve while three other malaria samples were
borderline positive, harbouring between 40-45UAU/mL
(Fig. 3b). Similarly, one EC sample from Bangladesh was
also positive. Hence the specificity of the ELISA was100%
on NEC and HAT samples, while varied from 70–90 % on
the TB, Pf malaria and EC samples used, (Table 2). The
agreement between the tests also suggested a slightly
higher sensitivity of the Leishmania Antigen Detect™
ELISA (Table 3). Cohen’s kappa revealed good correlation
between the tests on samples from Ethiopia and moderate
correlation on samples from Brazil (Table 3). Overall, the
performance of the Leishmania antigen ELISA from Kalon
was comparable to the Leishmania Antigen Detect™
ELISA on VL patients.
Performance of ELISAs compared to KAtex
KAtex is the only commercially available antigen detection
test and is based on detecting a Leishmania-specific carbo-
hydrate in urine [13]. To provide a direct comparison in
assay performance the expanded urine panel used for the
two ELISA kits was also evaluated with KAtex. While
KAtex also had a high specificity of 92 % for VL samples,
only moderate sensitivities at 61 % for Ethiopia (95 % CI of
45.4-74.9), 63 % for Sudan (95 % CI of 49.5-74.3), 69 % for
Bangladesh (95 % CI of 38.6-90.7) and 56 % for Brazil
(95 % CI of 39.9-70.9) were obtained (Table 1). The Leish-
mania Antigen Detect™ ELISA and Leishmania Antigen
ELISA from Kalon were more sensitive for VL samples
than KAtex.
Utility of antigen detection tests in monitoring VL
treatment success
To assess the potential of the Leishmania Antigen Detect™
ELISA and the Leishmania antigen ELISA from Kalon for
monitoring treatment, we evaluated a set of urine samples
from 42 confirmed Ethiopian VL patients starting at diag-
nosis prior to treatment start (Day 0) through Day 30 and
up to Day 180 post-treatment. Patients were provided a
standard 28 day treatment course of SSG, with the excep-
tion of two who were treated with AmBisome™ and one
with MEG. Initial cure and clinical cure were evaluated at
30 and 180 days, respectively, by resolution of clinical
symptoms and absence of parasites by microscopy. At Day
0, 40/42 patients were positive with a median response of
0.5 (Fig. 4a). The 2 patients who were negative by the
Leishmania Antigen Detect™ ELISA at Day 0 had low
parasite grade (1+ and 2+) by microscopy (data not
shown). At Day 30, there was a significant drop in the
Table 2 Specificity of the Leishmania Antigen Detect™ ELISA
and Leishmania Antigen ELISA
Samples Leishmania Antigen





NEC (n=36) 100 (90.3–100) 100 (90.3–100)
EC (n=10) 100 (69.1–100) 90 (55.5–99.7)
HAT (n=10) 100 (69.2–100) 100 (69.2–100)
Pf Malaria (n=10) 100 (69.2–100) 70.0 (34.8–93.3)
TB (n=10) 100 (69.2–100) 80.0 (44.4–97.5)
Fig. 3 Performance of Leishmania Antigen ELISA. a. Standard curve representing means of the signals obtained in the Leishmania Antigen ELISA
using the calibrated standards provided with the kit. b. Performance of Leishmania Antigen ELISA on urine samples from VL patients in Ethiopia
(n = 46), Sudan (n = 64), Bangladesh (n = 13) and Brazil (n = 43) compared to NEC (n = 49), EC from Bangladesh (n = 10) and OD (n = 30). OD
consists of samples from patients with HAT (n = 10), P. falciparum malaria (n = 10) and tuberculosis (n = 10) in UAU/mL. Lines represent median
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Table 3 Agreement between Leishmania Antigen Detect™ ELISA and the Leishmania Antigen ELISA on VL patient urine samples
from Ethiopia, Sudan, Brazil and Bangladesh are tabulated
Test Agreement Leishmania Antigen Detect™ ELISA Correlationf/c)
95% ClPositive Negative
Ethiopia (n=46)
Leishmania Antigen ELISA Positive 35 0 0.802 (0.59- 1.00)
Negative 3 8
Sudan (n=64)
Leishmania Antigen ELISA Positive 50 0 0.207 (-0.04-0.45)
Negative 12 2
Brazil (n=43)
Leishmania Antigen ELISA Positive 34 1 0.551 (-0.21-0.89)
Negative 4 4
Bangladesh (n=13)
Leishmania Antigen ELISA Positive 10 0 Nd
Negative 3 0
Fig. 4 Performance of Leishmania Antigen Detect™ ELISA and Leishmania Antigen ELISA on treatment follow- up urine samples from Ethiopia.
a. Mean ELISA signals of 42 VL patients undergoing SSG, MEG or L-AmB treatment in Ethiopia at initiation (Day 0) and post initiation (Days 30 and
180) of treatment as measured by the Leishmania Antigen Detect™ ELISA. Dotted line indicates cut-off value for positivity as calculated from the
mean of negative controls added 3 standard deviations. b. UAU/mL for 42 VL patients undergoing SSG, MEG or L-AmB treatment in Ethiopia at
initiation (Day 0) and post initiation (Days 30 and 180) of treatment as measured by the Leishmania Antigen ELISA c. Positivity percentage of the
Leishmania Antigen Detect™ ELISA (Black bars) and Leishmania Antigen ELISA (dark gray bars) compared to KAtex (light gray bars) on VL patient
urine samples from Ethiopia at initiation (Day 0) and post initiation (Days 30 and 180) of treatment
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median to 0.1 and a concomitant drop in positivity to 9/
42 patients (Fig. 4a). The 9 patients who were still positive
at Day 30 had significantly higher parasite grades at diag-
nosis (4+ to 5+). None of the patients tested positive at
Day 180 (Fig. 4a). The decline in response thus, reflected
parasite clearance and clinical cure.
The samples were also evaluated with Leishmania
Antigen ELISA and KAtex. The trend of UAU/mL was
very similar to the signals observed with the Leishmania
Antigen Detect™ ELISA, though the sensitivity at Day 0
was slightly lower. At Day 0, 38/42 patients tested posi-
tive with a median value of 1,472 UAU/mL which rapidly
decreased by Day 30, when only 15/42 patients were still
positive with significantly less urinary antigens, ranging
from 33–248 UAU/mL (Fig. 4b). By Day 180, except for
five patients, all were negative with no detectable urine
antigens (Fig. 4b). The antigens detected in the positive
patients ranged from 40–172 UAU/mL with one being
borderline positive, with 40–45 UAU/mL. KAtex was less
sensitive than ELISAs for diagnosis of confirmed VL pa-
tients at Day 0, when sensitivity was >90 % for both ELI-
SAs compared to only 64 % by KAtex (Fig. 4c). At Day 30,
only 2 % were positive by KAtex compared to 21 % by the
Leishmania Antigen Detect™ ELISA and 36 % by the
Leishmania Antigen ELISA (Fig. 4c). At Day 180, 7 % of
the patients were still positive by KAtex and 11 % by the
Leishmania Antigen ELISA but none by the Leishmania
Antigen Detect™ ELISA (Fig. 4c). Based on this data set,
the Leishmania Antigen Detect™ ELISA and the Leish-
mania Antigen ELISA were more sensitive than KAtex for
initial detection of active VL and appear to be better tools
for monitoring treatment efficacy.
Discussion
Early diagnosis and efficacious treatment are the keys to
VL management. VL treatment options are plagued by
high costs, severe systemic side effects and unrespon-
siveness. Though simple and accurate diagnostic tests
are widely available to confirm VL, they are not suitable
to monitor treatment efficacy and cure. According to the
WHO’s recommendations, tests for treatment efficacy
and cure should be the “highest research priority” in VL
control [20]. At this time, microscopy and KAtex are the
only available tests to follow treatment [11]. Though
attempts have been made to develop capture ELISAs to
detect antigens in the urine of VL patients, they have
not yet progressed to standardized tests [21].
With the goal of developing a Leishmania antigen
detection test suitable for following treatment, we devel-
oped the Leishmania Antigen Detect™ ELISA. As a tool
for monitoring treatment, the Leishmania Antigen De-
tect™ ELISA was sensitive, specific and suggested parasite
clearance during clinical cure (Fig. 3). Thus, in terms of
performance, the test represents a significant improve-
ment over current options. The ELISA also has practical
advantages over KAtex such as not requiring the boiling
of urine, thus improving convenience of the assay. The
profile of Leishmania antigens in the urine of VL patients
can be complex with not one dominating antigen detect-
able at all times [18]. The Leishmania Antigen Detect™
ELISA contains antibodies raised against a diverse panel
of antigens derived from L. donovani. The diversity of the
antibody repertoire could be a reason for the high sensitiv-
ity of the Leishmania Antigen Detect™ ELISA compared
to KAtex and other previous capture ELISAs, both in-
house and documented, which were developed to detect
single antigens [21, 22] (data not shown). The Leishmania
Antigen Detect™ ELISA also performed comparably to the
Leishmania Antigen ELISA, an antigen detection ELISA
developed by Kalon Biological Ltd. as an improvement over
their KAtex test. The Katex and Kalon VL ELISA are both
based on polyclonal antibody response to whole promasti-
gotes. However the Leishmania Antigen ELISA utilizes
affinity purified polyclonal antibodies based on an antigen
similar to the whole cell lysate. The format for both ELISAs
is similar, and so are their performances on urine samples
from VL patients and controls (Table 1). However, the
Leishmania Antigen Detect™ ELISA was more specific for
VL based on the OD samples tested in this study (although
endemic controls were not tested) as well as more sensitive
on VL samples from endemic regions in which L. donovani
is the causative agent, namely Sudan and Bangladesh.
Early detection of treatment non- responsiveness could
help alter treatment options in time to prevent adverse
outcomes such as mortality. It may be possible to refine
and use the ELISAs as a means of identifying treatment
non- responsiveness, if detection of antigen in urine can
be considered a surrogate for parasite burden. A concern
for VL patients infected with L. donovani is the potential
of developing PKDL after clinical cure [23, 24]. As much
as 50 % of treated VL patients in Sudan, South Sudan and
Northern Ethiopia develop PKDL, 6 months after treat-
ment [24]. It is probable that antigen excretion in urine
reflects parasite clearance by the drug, which occurs
within 26 days for both antimoniates and Amphotericin B
[25–28]. None of the treated patients in this study
relapsed or developed PKDL as of this time. Since these
patients were from Southern Ethiopia where relapse and
PKDL are rare compared to other regions of East Africa,
it is not possible to draw any conclusions regarding the
dynamics of antigen presence in urine and the risk for
PKDL development. The testing of PKDL and Cutaneous
Leishmaniasis urines would be useful to determine if both
these two ELISAs are specific to Visceral Leishmaniasis.
Though originally developed as a tool to monitor
treatment success, the high sensitivity of the ELISAs on
VL patient samples from diverse endemic regions indicates
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that it also has potential as a tool for primary diagnosis. It
could serve as an alternative in cases where currently used
diagnostic tests are not as effective. Such a situation can
arise in individuals with low antibody titers to diagnostic
antigens like rK39, and immune suppression co- morbid-
ities such as HIV [14, 29]. Accurate diagnosis in such diffi-
cult scenarios can significantly aid case management. The
Leishmania Antigen ELISA (Kalon Biological Ltd.) was
designed as a proof of cure and test for treatment failure. It
was not developed to be a screening assay as not enough
endemic controls or other endemic disease urines were
used in the initial performance evaluation. The two ELISAs
detect Leishmania antigens but with different sensitivities
based on their cut- off for positivity (Table 3). Further
refinement of the cut- off for positivity will be undertaken
in future based on data obtained from an expanded panel
of samples.
The Leishmania Antigen Detect™ ELISA and the Leish-
mania Antigen ELISA could serve as a standardized tool to
measure the effectiveness of emerging treatment regimens
in clinical trials and help make policies on implementation
of new drug regimens in endemic regions [11]. Currently,
splenic biopsy or PCR are used as a surrogate for parasite
burdens in most trials involving new treatment regimens
[26, 30]. Splenic biopsy is invasive, and not amenable for re-
peated sampling. PCR is expensive and hard to standardize
among laboratories. As a direct detection test that reflects
parasite burdens, the ELISAs could be the alternative with
non- invasive sampling, high sensitivity and a quantitative
read- out being distinct advantages.
Our study provides compelling data for further
refinement of the Leishmania Antigen Detect™ ELISA
for deployment in endemic regions for multiple VL
management purposes. Further assessments with sam-
ples from endemic regions reflecting co- infections
with TB or HIV and different treatment regimens are
needed to qualify the Leishmania Antigen Detect™
ELISA for clinical use, including diagnosis and test of
cure. Development of lateral flow assay formats of
both ELISAs, which would be more suitable for com-
munity use should also be envisioned.
Conclusions
The lack of standardized tools to monitor treatment ham-
pers VL management in many ways. An effective tool that
reflects parasite burden in VL: patients can help assess the
suitability of the treatment regimen, foresee treatment fail-
ure and possibly predict post- treatment complications such
as relapse. In this study, we have compared the suitability
of two direct detection sandwich- ELISA based standard-
ized tests, developed to detect Leishmania– specific anti-
gens in the urine of patients. Both displayed high sensitivity
and specificity on samples from the major endemic regions
as well as, reflected parasite clearance in patients
undergoing antimonial treatment in Ethiopia, a significant
improvement over KATex, the only existing antigen detec-
tion test in the market. The ELISAs are user- friendly and
quantitative and are suitable for deployment in routine
care. They could also be adapted to a more cost- effective
and point- of - care format such as lateral flow. Thus, we
consider the tests a promising alternative to existing tests
to monitor treatment and cure and worthy of further as-
sessment and wide- spread deployment in endemic regions.
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